Stocks and Investing Stocks and Investing
Wed, May 3, 2023

Michael Ulz Maintained (ARWR) at Hold with Increased Target to $40 on, May 3rd, 2023


Published on 2024-10-28 03:18:22 - WOPRAI, Michael Ulz
  Print publication without navigation


Michael Ulz of Morgan Stanley, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Hold with Increased Target from $37 to $40 on, May 3rd, 2023.

Michael has made no other calls on ARWR in the last 4 months.



There are 8 other peers that have a rating on ARWR. Out of the 8 peers that are also analyzing ARWR, 1 agrees with Michael's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • William Pickering of "Bernstein" Initiated at Hold and Held Target at $27 on, Tuesday, March 21st, 2023


These are the ratings of the 7 analyists that currently disagree with Michael


  • David Hoang of "SMBC Nikko" Initiated at Buy and Held Target at $80 on, Wednesday, April 26th, 2023
  • Mani Foroohar of "SVB Securities" Upgraded from Hold to Buy and Increased Target to $35 on, Wednesday, April 12th, 2023
  • Keay Nakae of "Chardan Capital" Reiterated at Strong Buy and Held Target at $60 on, Friday, February 10th, 2023
  • Patrick Trucchio of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $90 on, Friday, February 10th, 2023
  • Mayank Mamtani of "B. Riley Securities" Maintained at Strong Buy with Decreased Target to $55 on, Wednesday, February 8th, 2023
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Decreased Target to $52 on, Tuesday, February 7th, 2023
  • Joel Beatty of "Baird" Maintained at Buy with Decreased Target to $58 on, Tuesday, February 7th, 2023
Contributing Sources